Company Product Description Indication Status
Beigene Ltd., of Beijing Tislelizumab Anti-PD-1 antibody Classical Hodgkin lymphoma Approved by China’s NMPA for use in patients who have received at least 2 prior therapies
Merck & Co. Inc., of Kenilworth, N.J., and Astrazeneca plc, of Cambridge, U.K. Lynparza (olaparib) PARP inhibitor Metastatic pancreatic adenocarcinoma Approved by FDA for use as maintenance treatment in adults with deleterious or suspected deleterious germline BRCA-mutated disease that has not progressed on at least 16 weeks of first-line platinum-based chemotherapy regimen
Morphosys AG, of Martinsried, Germany Tafasitamab Anti-CD19 antibody Relapsed or refractory diffuse large B-cell lymphoma Submitted BLA to FDA
Savara Inc., of Austin, Texas  Molgradex Inhaled formulation of recombinant human GM-CSF Autoimmune pulmonary alveolar proteinosis FDA granted breakthrough therapy designation

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments